Om os
We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, our passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines. We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinaryTM experience. Established in 1999, we are headquartered in Copenhagen, Denmark with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com. Disclaimer: http://bit.ly/GENDisclaimer
- Websted
-
http://www.genmab.com
Eksternt link til Genmab
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 1.001 – 5.000 medarbejdere
- Hovedkvarter
- Copenhagen V
- Type
- Aktieselskab
Beliggenheder
Medarbejdere hos Genmab
-
Hinrich Göhlmann
Scientific Director specializing in 𝐇𝐢𝐠𝐡-𝐃𝐢𝐦𝐞𝐧𝐬𝐢𝐨𝐧𝐚𝐥 𝐁𝐢𝐨𝐥𝐨𝐠𝐲 | Bridging Science, Data, and Technology
-
Amy D.
Director, Digital Products, Experience Management @ Genmab | Digital Transformation
-
Javier Pintado
Vice President, Global Marketing at Genmab
-
Caroline Eilering
Opdateringer
-
In honor of #CancerImmunotherapyMonth, Genmab recognizes the revolutionary advancements in immunology that are transforming the fight against cancer. Our colleague, Pauline de Goeje, works to design and test new antibody products in the immune-oncology space, with a goal of harnessing the incredible power of our own immune system to target and eliminate tumor cells. Learn more about our unstoppable teams here: http://gmab.ly/F0t150Sqhyo.
-
At Genmab, our extra[not]ordinary™ colleagues are empowered to innovate, build solutions, and execute. Vibeke Leth, Medical Portfolio Operations Manager, shares her perspective on how she emulates these values within her teams. To be part of the extra[not]ordinary™, visit: https://bit.ly/3lTqAPf. #ExtraNotOrdinary #JoinGenmab
-
Genmab is proud to support Out in Science, Technology, Engineering & Mathematics (oSTEM). This Pride Month, oSTEM is awarding scholarships to LGBTQIA+ students pursuing degrees in the sciences at a New Jersey university or college. We’re proud to contribute to this initiative in our local community. To learn more about our Diversity, Equity and Inclusion ambitions, visit: http://gmab.ly/oPv650Sj8lb. #CommunityAtGenmab #PrideMonth
-
In observance of Juneteenth, Genmab is supporting the Stoutsburg Sourland African American Museum. The museum plays a vital role in preserving African American history, educating the public, promoting diversity and inclusion, and fostering a sense of community and cultural pride in New Jersey. We are proud to continue supporting the important work of this museum. To learn more about our DE&I efforts, click here: http://gmab.ly/uFnR50Sk4ta #Juneteenth #CommunityAtGenmab
-
#DYK that what makes antibodies extraordinary is their ability to distinguish among countless foreign invaders? When encountering a pathogen, antibodies either neutralize it directly or tag it for elimination by other immune cells. Additionally, they play a crucial role in immunological memory, enabling a swift and potent response to previously encountered pathogens. Learn more about our science: http://gmab.ly/J5BI50Skm9V #innovation
-
Our leaders including Robyn Bilmes, Senior Vice President, Head of Medical Affairs, Julie Blaedel, Vice President, Global Medical Affairs Hematology, Judith Klimovsky, Executive Vice President & Chief Development Officer, and Kathy Amiri, Vice President, Global Medical Affairs Solid Tumors discuss Genmab’s efforts to address unmet needs for patients with cancer. Learn more about our oncology pipeline: https://lnkd.in/ejvp63Ty #ASCO24 #EHA24
-
On the heels of our presentation at #EHA2024, we’re excited to share that The Lancet Haemotology has published data from a study evaluating our investigational treatment option for relapsed/refractory follicular #lymphoma, in partnership with AbbVie. Learn more: http://gmab.ly/cSSr50Sk13E
-
Did you hear? Genmab’s website has a new stories page showcasing our Extra[Not]Ordinary™ people. Our website highlights how our unstoppable teams are dedicated to expanding our pipeline of antibody medicines and leveraging innovative technologies to make a difference for patients with cancer and other serious diseases. Click the link below to read our stories on the newest innovations and latest insights on how Genmab is working to transform lives. http://gmab.ly/aIUf50Sj80W #innovation #CommunityatGenmab
-
Welcome to Genmab’s Knock-Your-Socks-Off-News, a monthly newsletter covering our current happenings across the globe. Follow along with us on our journey for more updates as we advance innovation and continue to work towards our goal of transforming the lives of patients through antibody medicines. #culture #news #healthcare
Tilsvarende sider
Finansiering
Seneste runde
Post IPO-egenkapital134.000.000,00 US$